Titan Pharmaceuticals, Inc. (TTNP) Earnings History
Net Loss30 years of earnings data (1995–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Titan Pharmaceuticals, Inc. (TTNP) Earnings Overview
As of June 23, 2026, Titan Pharmaceuticals, Inc. (TTNP) reported trailing twelve-month net income of -$3M, reflecting +29.4% year-over-year growth. The company earned $-2.63 per diluted share over the past four quarters.
Looking at the long-term picture, TTNP's historical earnings data spans multiple years. The company achieved its highest annual net income of $10M in fiscal 2013.
Titan Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$158M net income, -297.1% margin), MTLS ($10M net income, 2.9% margin), ORMP ($110M net income, 3202.5% margin), TTNP has comparable earnings metrics. Compare TTNP vs NKTR →
TTNP Earnings vs Peers
Earnings metrics vs comparable public companies
TTNP Historical Earnings Data (1995–2024)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$5M | +15.5% | -$5M | $-5.23 | - | - |
| 2023 | -$6M | +45.3% | -$7M | $-7.41 | -556900.0% | -727700.0% |
| 2022 | -$10M | -25.4% | -$10M | $-15.15 | -16961.7% | -17058.3% |
| 2021 | -$8M | +60.9% | -$9M | $-4.06 | -531.7% | -613.0% |
| 2020 | -$21M | -28.8% | -$7M | $-10.38 | -428.4% | -151.9% |
| 2019 | -$16M | -78.3% | -$17M | $-9.83 | -445.6% | -466.5% |
| 2018 | -$9M | +36.9% | -$8M | $-47.59 | -152.6% | -139.8% |
| 2017 | -$14M | -378.6% | -$15M | $-121.34 | -6654.4% | -6745.1% |
| 2016 | $5M | +145.5% | $4M | $36.01 | 34.1% | 28.8% |
| 2015 | -$11M | -369.4% | -$7M | $-101.24 | -675.0% | -404.5% |
| 2014 | -$2M | -124.7% | -$3M | $-25.35 | -65.9% | -95.3% |
| 2013 | $10M | +164.0% | $-891,000 | $95.40 | 92.7% | -8.5% |
| 2012 | -$15M | +0.2% | -$8M | $-225.96 | -213.3% | -117.6% |
| 2011 | -$15M | -122.5% | -$11M | $-249.23 | -373.7% | -258.3% |
| 2010 | -$7M | -16.1% | -$6M | $-114.20 | -67.7% | -59.7% |
| 2009 | -$6M | +76.9% | -$6M | $-99.66 | -7450.6% | -7360.8% |
| 2008 | -$25M | -44.1% | -$26M | $-431.92 | -36328.6% | -37028.6% |
| 2007 | -$18M | -12.1% | -$18M | $-406.32 | -73529.2% | -76804.2% |
| 2006 | -$16M | +29.9% | -$16M | $-411.06 | -49178.1% | -51396.9% |
| 2005 | -$22M | +13.6% | -$23M | $-681.41 | -25238.2% | -25900.0% |
| 2004 | -$26M | +13.0% | -$26M | $-820.39 | -83883.9% | -85096.8% |
| 2003 | -$30M | -6.1% | -$31M | $-1060.34 | -33583.1% | -35027.0% |
| 2002 | -$28M | -61.4% | -$32M | $-1009.38 | -974.5% | -1106.6% |
| 2001 | -$17M | +7.0% | -$24M | $-626.56 | -382.0% | -528.2% |
| 2000 | -$19M | -66.3% | -$19M | $-726.84 | -999.4% | -1007.1% |
| 1999 | -$11M | -6.6% | -$12M | $-694.36 | -3766.7% | -3966.7% |
| 1998 | -$11M | -1866.7% | -$11M | $-800.60 | -10600.0% | -11400.0% |
| 1997 | $600,000 | +104.7% | -$8M | $39.60 | 3.4% | -44.6% |
| 1996 | -$13M | -10.3% | -$11M | $-1030.02 | -4300.0% | -3533.3% |
| 1995 | -$12M | - | -$9M | $-1531.01 | -11700.0% | -9400.0% |
Download Data
Export TTNP earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
31+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TTNP — Frequently Asked Questions
Quick answers to the most common questions about buying TTNP stock.
What is TTNP earnings per share (EPS)?
TTNP trailing twelve-month (TTM) diluted EPS is $-2.63, reflecting +29.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1995 to 2024 is available in the table on this page.
What is Titan Pharmaceuticals, Inc.'s net income?
Titan Pharmaceuticals, Inc. (TTNP) trailing twelve-month net income is $-3M as of 2024. Earnings grew +29.4% year-over-year.
Is TTNP profitable?
TTNP is not currently profitable on a TTM basis, reporting a net loss of $-3M. Net margin is N/A. Investors should monitor for a return to profitability.
What is TTNP's earnings growth rate?
TTNP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1995 to 2024.
What are TTNP's profit margins?
Titan Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -103.6%.
Is TTNP growing earnings?
Yes, TTNP earnings are accelerating — EPS growth of +29.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-3M. Earnings momentum is strengthening.
What was TTNP's best earnings year?
Titan Pharmaceuticals, Inc.'s highest annual net income on record is $10M, achieved in fiscal year 2013. Earnings history on this page spans 1995 to 2024 and includes all annual and quarterly figures.
What were TTNP's earnings last quarter?
TTNP's most recent reported quarter was Q2 2025. Net income was $-689000.00 with diluted EPS of $-0.65. For a full breakdown of all quarters, see the quarterly earnings table on this page.